Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Abstract Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin’s Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons includ...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-09-01
|
| Series: | Molecular Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s10020-018-0051-4 |